Analysis
Value based pricing for NHS drugs: an opportunity not to be missed?
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39434.500185.25 (Published 31 January 2008) Cite this as: BMJ 2008;336:251
Related articles
- Observations Published: 10 November 2010; BMJ 341 doi:10.1136/bmj.c6378
- Head To Head Published: 15 May 2008; BMJ 336 doi:10.1136/bmj.39563.493218.AD
- Editorial Published: 01 March 2007; BMJ 334 doi:10.1136/bmj.39136.464421.BE
- Editorial Published: 10 January 2008; BMJ 336 doi:10.1136/bmj.39454.496748.80
See more
- Communicating risk to patients in the emergency departmentBMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437
- Biological treatment is approved for severe eosinophilic asthmaBMJ December 01, 2016, 355 i6472; DOI: https://doi.org/10.1136/bmj.i6472
- Patient care is at risk from lack of new funds in autumn statement, healthcare leaders warnBMJ November 24, 2016, 355 i6356; DOI: https://doi.org/10.1136/bmj.i6356
- Government must be clearer in its claims about NHS funding, says statistics watchdogBMJ November 24, 2016, 355 i6340; DOI: https://doi.org/10.1136/bmj.i6340
- US must address addiction as an illness, not as a moral failing, Surgeon General saysBMJ November 22, 2016, 355 i6265; DOI: https://doi.org/10.1136/bmj.i6265
Cited by...
- Patient Experience and Attitudes Toward Addressing the Cost of Breast Cancer Care
- Reading a cost-effectiveness or decision analysis study: Five things to consider
- NICE is dead; long live NICE
- A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
- Drug pricing, NICE, and the PPRS: government gets it right
- The future role of NICE
- Economics of biological therapies
- Two Ideas To Increase Innovation And Reduce Pharmaceutical Costs And Prices
- NICE guidelines for the use of drug-eluting stents: how do we establish worth?
- Should patients be able to pay top-up fees to receive the treatment they want? No
- Not dead yet